Article ID Journal Published Year Pages File Type
3294083 Gastroenterology 2013 11 Pages PDF
Abstract
Although mesalamine 4.8 g/day was not statistically different from placebo for induction of remission in patients with mildly to moderately active UC, based on an intent-to-treat analysis, the totality of the data supports a benefit of treatment. Central review of endoscopic images is critical to the conduct of induction studies in UC; ClinicalTrials.gov Number, NCT01059344.
Related Topics
Health Sciences Medicine and Dentistry Gastroenterology
Authors
, , , , , , , , , , , , , , ,